Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: We treated 16 patients with predominantly oropharyngeal primary tumors, including 10 patients with T4 or N3 disease. Febrile neutropenia occurred toward the end of radiotherapy in three out of six patients treated on the initial dose level. Two of these patients also developed grade 4 acute radiation reactions. Another 10 patients were treated with the same doses, but the week 5 and week 6 tirapazamine doses were omitted. This resulted in less neutropenia and only one dose-limiting toxicity (DLT) ( febrile neutropenia), and eight out of 10 patients completed treatment without any dose omissions. In these 10 patients, the acute radiation toxicities were not obviously enhanced compared with chemoradiotherapy regimens using concurrent platinum and fluorouracil. 18F misonidazole scans detected hypoxia in 14 of 15 patients at baseline, with only one patient having detectable hypoxia at the end of treatment. With a median follow-up of 2.7 years, the 3-year failure-free survival rate was 69% (SE, 12%), the 3-year local progression-free rate was 88% (SE, 8%), and the 3-year overall survival rate was 69% (SE, 12%). CONCLUSION:
|
Authors | D Rischin, L Peters, R Hicks, P Hughes, R Fisher, R Hart, M Sexton, I D'Costa, R von Roemeling |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 19
Issue 2
Pg. 535-42
(Jan 15 2001)
ISSN: 0732-183X [Print] United States |
PMID | 11208848
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Radiation-Sensitizing Agents
- Radiopharmaceuticals
- Triazines
- fluoromisonidazole
- Fluorodeoxyglucose F18
- Tirapazamine
- Misonidazole
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Squamous Cell
(diagnostic imaging, drug therapy, metabolism, radiotherapy)
- Cell Hypoxia
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Dose Fractionation, Radiation
- Drug Administration Schedule
- Fluorodeoxyglucose F18
- Head and Neck Neoplasms
(diagnostic imaging, drug therapy, metabolism, radiotherapy)
- Humans
- Middle Aged
- Misonidazole
(analogs & derivatives)
- Radiation-Sensitizing Agents
(administration & dosage)
- Radiopharmaceuticals
- Survival Analysis
- Tirapazamine
- Tomography, Emission-Computed
- Triazines
(administration & dosage)
|